公开(公告)号：US08518644B2

公开(公告)日：2013-08-27

申请号：US11813450

申请日：2006-07-06

申请人： Toshihiro Tanaka ,  Yusuke Nakamura ,  Yozo Ohnishi ,  Koichi Ozaki ,  Aritoshi Iida ,  Masatsugu Hori

发明人： Toshihiro Tanaka ,  Yusuke Nakamura ,  Yozo Ohnishi ,  Koichi Ozaki ,  Aritoshi Iida ,  Masatsugu Hori

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6876 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172

摘要： An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and the advancement of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging an inflammatory disease which comprises detecting at least 1 type of genetic polymorphism existing in at least one gene selected from the group consisting of the LBP-32 gene, the TSBP gene, and the WAP gene.

摘要翻译： 本发明的目的是鉴定与炎性疾病如心肌梗塞的发病和进展相关的新型单核苷酸多态性（SNP）。 本发明提供了一种判断炎症性疾病的方法，该方法包括检测存在于选自LBP-32基因，TSBP基因和WAP基因的至少一种基因中的至少1种遗传多态性。

公开(公告)号：US20130108664A1

公开(公告)日：2013-05-02

申请号：US13639935

申请日：2011-04-07

申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

IPC分类号： C07K7/06

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/4738

摘要： Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor.

摘要翻译： 本文描述了衍生自SEQ ID NO：21的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物特别用于治疗癌症和肿瘤，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌， 食管癌，胃癌，胃弥漫型癌，肺癌，淋巴瘤，前列腺癌，SCLC和软组织肿瘤。

公开(公告)号：US20130095128A1

公开(公告)日：2013-04-18

申请号：US13638272

申请日：2011-03-30

申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

IPC分类号： C07K7/06

CPC分类号： C07K7/06 ,  A61K39/0011 ,  A61K2039/572

摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.

摘要翻译： 衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留必需的HLA结合和/或CTL诱导性 的原始序列。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包​​括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌 ，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。

公开(公告)号：US20130044218A1

公开(公告)日：2013-02-21

申请号：US13639924

申请日：2011-04-14

申请人： Kodai Matsuda ,  Makoto Aimura ,  Yusuke Nakamura

发明人： Kodai Matsuda ,  Makoto Aimura ,  Yusuke Nakamura

IPC分类号： H04N7/18

CPC分类号： B60R1/00 ,  B60R2300/105 ,  B60R2300/106 ,  B60R2300/205 ,  B60R2300/207 ,  B60R2300/307 ,  B60R2300/8033 ,  B60R2300/8093 ,  G06K9/00805 ,  G06K9/00838 ,  G06T3/00 ,  G06T7/74 ,  G06T2207/10012 ,  G06T2207/30196 ,  G06T2207/30261 ,  G08G1/0962 ,  G08G1/166

摘要： The device for monitoring surroundings of a vehicle is provided with means for detecting objects in the surroundings of the vehicle based on image acquired by an imaging device, display devices for displaying on display screens display images that are produced based on the captured image, and alerting means for alerting a driver of the existence of an object through the display devices when an object is detected. The display devices are placed at a plurality of locations visible from the driver. The alerting means reduces volume of information to be displayed on the display screen of the display device that requires large movement of line of sight of the drive for the driver to recognize the display screen from the reference line of sight that looks straight ahead.

摘要翻译： 用于监视车辆周围环境的装置设置有用于基于由成像装置获取的图像来检测车辆周围的物体的装置，用于在显示屏幕上显示的显示装置显示基于所捕获的图像产生的图像，以及警报 用于在检测到对象时通过显示装置警告驾驶员存在对象的装置。 显示装置被放置在从驾驶员可见的多个位置处。 警报装置减少要显示在显示装置的显示屏幕上的信息的体积，该信息需要驱动器的视线的大的移动以便从直视前方的参考视线识别显示屏幕。

公开(公告)号：US20130034566A1

公开(公告)日：2013-02-07

申请号：US13519127

申请日：2009-12-28

申请人： Yasuhiro Shiba ,  Hiroki Yoshioka ,  Shinji Yamamoto ,  Aiko Kudo ,  Ryuji Ohsawa ,  Pohsing Ng ,  Yusuke Nakamura ,  Keigo Endo

发明人： Yasuhiro Shiba ,  Hiroki Yoshioka ,  Shinji Yamamoto ,  Aiko Kudo ,  Ryuji Ohsawa ,  Pohsing Ng ,  Yusuke Nakamura ,  Keigo Endo

IPC分类号： C07K16/18 ,  A61P35/00 ,  G01N33/53 ,  C07K17/00 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/065 ,  C07K2317/41 ,  C07K2317/56 ,  G01N33/574 ,  G01N2333/705

摘要： The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

摘要翻译： 本发明涉及可用放射性同位素标记的抗CDH3抗体。 此外，本发明提供包含抗CDH3抗体作为活性成分的方法和药物组合物。 由于CDH3在胰腺，肺癌，结肠癌，前列腺癌，乳腺癌，胃癌或肝癌细胞中强烈表达，本发明可用于胰腺，肺癌，结肠癌，前列腺癌，乳腺癌，胃癌或肝癌的治疗。

公开(公告)号：US20130022975A1

公开(公告)日：2013-01-24

申请号：US13579463

申请日：2011-02-18

申请人： Kouichi Ozaki ,  Toshihiro Tanaka ,  Yusuke Nakamura

发明人： Kouichi Ozaki ,  Toshihiro Tanaka ,  Yusuke Nakamura

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172

摘要： An atherosclerotic disease such as myocardial infarction or angina pectoris is detected by analyzing a single nucleotide polymorphism on human chromosome 5p15.3, and by associating results of the analysis with the risk of the onset thereof. Examples of the single nucleotide polymorphism on human chromosome 5p15.3 include a nucleotide corresponding to the nucleotide at position 61 in the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and a polymorphism at a nucleotide which is in linkage disequilibrium with the above nucleotide.

摘要翻译： 通过分析人染色体5p15.3上的单核苷酸多态性，并通过将分析结果与其发病风险相关联来检测动脉粥样硬化性疾病如心肌梗塞或心绞痛。 人染色体5p15.3上的单核苷酸多态性的实例包括对应于SEQ ID NO：1，SEQ ID NO：2或SEQ ID NO：3的核苷酸序列中第61位的核苷酸的核苷酸， 与上述核苷酸连接不平衡的核苷酸。

公开(公告)号：US20120328638A1

公开(公告)日：2012-12-27

申请号：US13513543

申请日：2010-12-02

申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

IPC分类号： A61K39/00 ,  C12N15/12 ,  A61P35/00 ,  C12N5/0783 ,  C12N5/0784 ,  C12N15/85 ,  C12N5/10 ,  C07K7/08 ,  A61K31/7088

CPC分类号： C07K14/82 ,  A61K39/0011 ,  C07K14/4748

摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the MYBL2 gene that bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility, more particularly peptides having the amino acid sequence of SEQ ID NO: 5 and fragments thereof, are provided. The present invention further extends to peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, provided they retain cytotoxic T cell inducibility. Also provided as nucleic acids encoding any of the aforementioned peptides, antigen-presenting cells and isolated CTLs that target such peptides, and pharmaceutical agents and compositions including any of the aforementioned peptides, nucleic acids, and APCs as active ingredients. The components of the present invention have particular utility in connection with the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a postoperative recurrence thereof.

摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了衍生自结合HLA抗原并具有细胞毒性T淋巴细胞（CTL）诱导能力的MYBL2基因的表位肽，更特别是具有SEQ ID NO：5的氨基酸序列及其片段的肽。 本发明进一步扩展到包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加的肽，条件是它们保留细胞毒性T细胞诱导性。 还提供了编码任何上述肽，抗原呈递细胞和靶向这些肽的分离的CTL的核酸以及包含任何上述肽，核酸和APC作为活性成分的药物和组合物的核酸。 本发明的组分与癌症（肿瘤）的治疗和/或预防（即预防）和/或预防其术后复发有关。

公开(公告)号：US08339921B2

公开(公告)日：2012-12-25

申请号：US12453538

申请日：2009-05-14

申请人： Yusuke Nakamura

发明人： Yusuke Nakamura

IPC分类号： G11B7/00

CPC分类号： G11B20/1426 ,  G11B7/0065 ,  G11B2020/1457 ,  G11B2020/1469 ,  G11B2220/2504

摘要： An optical information recording/reproducing apparatus using holography comprises a signal generation unit that modulates input data, adds at least one control bit to each group of N bits, performs an NRZI-modulation on the modulated data, determines the at least one control bit such that a digital sum value of the NRZI-modulated data is 0, performs NRZI modulation on the data whose at least one control bit was determined, and rearranges the data to generate 2-dimensional data; a pickup that records the 2-dimensional data in a hologram disc and reproduces the 2-dimensional data from the hologram disc; and a signal processing unit that corrects the 2-dimensional data reproduced by the pickup, performs NRZI-modulation on the 2-dimensional data that has undergone a binarization operation, removes the at least one control bit added during the recording, and demodulates the data according to a modulation rule used during the recording.

摘要翻译： 使用全息术的光学信息记录/再现装置包括：信号产生单元，其对输入数据进行调制;将至少一个控制位加到每一组N位;对调制数据执行NRZI调制;确定至少一个控制位， NRZI调制数据的数字和值为0，对确定了至少一个控制位的数据执行NRZI调制，并重新排列数据以生成二维数据; 记录全息图盘中的二维数据的拾取器，并再现来自全息图盘的二维数据; 以及信号处理单元，其校正由拾取器再现的2维数据，对经过二值化操作的二维数据执行NRZI调制，去除在记录期间添加的至少一个控制位，并解调数据 根据记录期间使用的调制规则。

公开(公告)号：US20120308591A1

公开(公告)日：2012-12-06

申请号：US13515656

申请日：2010-12-13

申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

IPC分类号： A61K39/00 ,  C12N15/12 ,  C12N5/078 ,  C12N1/21 ,  C12N5/10 ,  A61K31/7088 ,  A61P35/00 ,  C12N15/63 ,  C07K7/06 ,  C12N15/85

CPC分类号： C07K7/06 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/57 ,  C07K14/705

摘要： Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.

摘要翻译： 描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段 这里。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。 本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

公开(公告)号：US20120308590A1

公开(公告)日：2012-12-06

申请号：US13513120

申请日：2010-11-30

申请人： Yasuharu Nishimura ,  Michiko Harao ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

发明人： Yasuharu Nishimura ,  Michiko Harao ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

IPC分类号： A61K39/00 ,  C07H21/04 ,  A61K31/7088 ,  A61P35/00 ,  A61K35/14 ,  C07K7/06 ,  C12N5/078

CPC分类号： A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/57 ,  C07K14/47

摘要： Oligopeptides having cytotoxic T cell inducibility and suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. Notable examples include oligopeptides having the amino acid sequence of SEQ ID NO: 1, 3, 5 or 6, wherein 1, 2, or several amino acids are optionally substituted, deleted, inserted or added so long as they retain the cytotoxic T cell inducibility of the original oligopeptides. Pharmaceutical formulations or “drugs” related to such oligopeptides suitable for treating or preventing cancers or tumors, as well as the post-operative recurrence thereof, are also described.

摘要翻译： 本文描述了具有细胞毒性T细胞诱导能力并且适用于癌症免疫治疗，尤其是癌症疫苗的背景下的寡肽。 值得注意的实例包括具有SEQ ID NO：1,3,5或6的氨基酸序列的寡肽，其中1,2或几个氨基酸任选被取代，缺失，插入或加入，只要它们保留细胞毒性T细胞诱导性即可 的原始寡肽。 还描述了与适用于治疗或预防癌症或肿瘤的这种寡肽相关的药物制剂或药物，以及其术后复发。